Royalties on Net Sales Value. The Licensee shall pay to the RPO a royalty of [●] per cent ([●]%) of the Net Sales Value of all Licensed Products, or any part thereof, sold or otherwise supplied by Licensee or its Affiliates.]
Royalties on Net Sales Value. The Licensee shall pay to Chroma a royalty of 5% (Five percent) of the Net Sales Value.
Royalties on Net Sales Value. 5.4.1 Orchard shall pay to UCLB during the Royalty Term, on a Gene Therapy Product by Gene Therapy Product basis, a royalty calculated as a particular Full Rate or Reduced Rate percentage of the Net Sales Value of the applicable Gene Therapy Product sold or disposed of by or on behalf of Orchard or its Sub-licensees, subject to the further provisions of this Clause 5 (a “Royalty”). Royalty payments shall be calculated by reference to the following percentage rates for the applicable Gene Therapy Product as follows: ADA SCID Product [***] [***] Perforin Deficiency Product [***] [***] MPS1 Product [***] [***] [***] [***] [***] LCR-EFS Platform Product sold under a Marketing Approval where the indication does not include ADA-SCID, Perforin Deficiency, MPS1 or [***] [***] [***]
5.4.2 Where a Gene Therapy Product (i) at the time and in the country of sale would, but for the licence granted hereunder, infringe a Valid Claim of a Joint Patent or a Valid Claim of a UCLB Patent; or (ii) incorporates or comprises one of the Vectors, or a Vector is used directly in the manufacture or delivery of that Gene Therapy Product; or (iii) uses or incorporates, or had used in its development, any of the (a) Principal Joint Know-how in the case of an ADA SCID Product; or (b) Principal LCR-EFS Know-how in the case of an LCR-EFS Platform Product; or (c) Principal MPS1 Know-how in the case of an MPS1 Product; or (d) Scheduled Perforin Know-how in the case of a Perforin Deficiency Product; or (e) [***] in the case of a [***]; or (iv) obtained a Marketing Approval through use and reliance (by inclusion in the Regulatory Submission) on (in whole or in part) Joint Clinical Data or (v) Exploited by Orchard benefits from any Regulatory Incentive assigned to Orchard hereunder in respect of such Gene Therapy Product, then in such cases the Royalty due for such Gene Therapy Product under Clause 5.4.1 shall be calculated by reference to the Full Rate, but in all other circumstances the Royalty due for Gene Therapy Products shall be calculated by reference to the Reduced Rate set out in the table under Clause 5.4.1.
5.4.3 Only one Royalty Rate shall be payable per unit of any Gene Therapy Product and the Royalty payable on an individual unit of any Gene Therapy Product shall be calculated only once and payable only once and calculated at the time of sale or disposal on an arm’s length basis to a Third Party either by Orchard or its Sub-licensee, or, if it was supplied other than as a sale o...
Royalties on Net Sales Value. The Licensee shall pay to ValiRx a royalty of 5% of the Net Sales Value.
Royalties on Net Sales Value. The Licensee shall pay to the RPO a royalty of [●] per cent ([●]%) of the Net Sales Value of all Developed Products and Services, or any part thereof, sold or otherwise supplied by Licensee or its Affiliates. [Minimum royalties. If the royalties payable under Clause 4.3 are less than [●] Euro (€[●]) (“Minimum Royalty”) in any calendar year, the Licensee shall pay to the RPO the amount by which such royalties are less than the Minimum Royalty within sixty (60) days of the end of such calendar year, failing which the RPO shall be entitled to terminate this Agreement and all licences granted under this Agreement by notice in writing to the Licensee given at any time after the expiry of the said sixty (60) day period. If this Agreement ends on any day other than the end of a calendar year, the Minimum Royalty due for that year shall be reduced, pro-rata, i.e. the minimum amount due shall be the Minimum Royalty for a complete year multiplied by the number of days of the final calendar year during which this Agreement was in force, and divided by three hundred and sixty five (365) days.] Payment frequency. Royalties due under this Agreement shall be paid within thirty (30) days of the end of each quarter ending on 31 March, 30 June, 30 September and 31 December, in respect of sales and other supplies of Developed Products and Services made during such quarter and within thirty (30) days of the termination of this Agreement. Payment terms. All sums due under this Agreement: are exclusive of Value Added Tax which where applicable will be paid by the Licensee to the RPO in addition; shall be paid in Euro in cash by transferring an amount in aggregate to the following account number [●], sort code [●], account name [●], held with [●] Bank plc, [address]; shall be made without deduction of income tax or other taxes charges or duties that may be imposed, except insofar as the Licensee is required to deduct the same to comply with applicable laws. The Parties shall cooperate and take all steps reasonably and lawfully available to them, at the reasonable expense of the RPO, to avoid deducting such taxes and to obtain double taxation relief. If the Licensee is required to make any such deduction it shall provide the RPO with such certificates or other documents as it can reasonably obtain to enable the RPO to obtain appropriate relief from double taxation of the payment in question; and shall be made by the due date, failing which the RPO may charge interest on any outst...
Royalties on Net Sales Value. The Licensee shall pay to UCLB a royalty being a percentage of the Net Sales Value of all Licensed Products or any part thereof used, sold or disposed of by or on behalf of the Licensee or its Affiliates as follows:
4.4.1 [****]% ([****] percent) in case cumulative Net Sales Value is equal to or less than $[****] ([****] US dollars); and
4.4.2 [****]% ([****] percent) in case cumulative Net Sales Value is above $[****] ([****] US dollars).
Royalties on Net Sales Value. The Licensee shall pay to UCLB a royalty being a percentage of the Net Sales Value of all Licensed Products or any part thereof used, sold or disposed of by or on behalf of the Licensee or its Affiliates as follows:
Royalties on Net Sales Value. The Licensee shall pay to the University a royalty of [●] per cent ([●]%) of the Net Sales Value of all Licensed Products, or any part thereof, sold, licensed or otherwise supplied by Licensee or its Affiliates.
Royalties on Net Sales Value. The Licensee shall pay to Hypergenomics a royalty of 5% of the Net Sales Value.
Royalties on Net Sales Value. The Licensee shall pay to Volition a royalty of 5% of the Net Sales Value.
